Who is sponsoring NCT01008956?

NCT01008956 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT01008956?

Interventions: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A.

What is the status of NCT01008956?

NCT01008956 is currently WITHDRAWN.

Last reviewed 2015-03-19 · How we verify

Immunogenicity and Safety Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine GSK2340274A in Adults 18 to 64 Years of Age

NCT01008956 Phase 2 WITHDRAWN

This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 18 to 64 years of age.

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	WITHDRAWN
Start date	2010-04
Completion	2010-10

Conditions

Influenza

Interventions

GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A

Primary outcomes

Humoral immune response in terms of Hemagglutination Inhibition (HI) antibodies (Vaccine virus-homologous responses) — At Day 21 after vaccination